Tevimbra (tislelizumab)
Research Synopsis
- * Recent studies suggest that tislelizumab, when combined with treatments like transcatheter arterial chemoembolization (TACE) and surgery, could significantly improve clinical responses and survival rates in patients with HCC and NSCLC.
- * A case report highlighted its efficacy in a 57-year-old woman with HCC less likely to undergo curative treatment due to co-infections with HIV and HBV, exemplifying potential new treatment strategies for complex cases.
- * Although tislelizumab shows promise at improving outcomes in solid tumors, cases of secondary adrenal insufficiency have been reported following its use, necessitating careful monitoring and potential treatment modifications.
- * In another study, it was found that patients with stage II-III NSCLC experienced better progression-free and overall survival rates when tislelizumab treatment was combined with surgical interventions compared to chemotherapy alone.
- * The efficacy of tislelizumab in treating Diffuse Large B-Cell Lymphoma (DLBCL) was investigated, revealing that it positively affects cytokine levels and T-cell populations, indicating a boost in immune function.
- * Tislelizumab has also been evaluated in patients with relapsed or refractory classical Hodgkin lymphoma, showing substantial response rates with manageable side effects, underscoring its clinical utility.
- * The ongoing evolution of immunotherapy, particularly checkpoint inhibitors, has positioned tislelizumab as a key player in the field, with its future potentially involving combination therapies and different tumor types.
- * Overall, the sentiment surrounding tislelizumab is largely positive due to its emerging effectiveness and the potential to enhance treatment protocols in oncology, despite the need to address associated adverse effects.
- * Further clinical trials are necessary to solidify its role and optimize therapeutic strategies for patients across various cancer types.
Tevimbra (tislelizumab)
Case report: Complete response after transcatheter arterial chemoembolization combined with donafenib plus tislelizumab therapy for hepatocellular carcinoma with main trunk portal vein tumor thrombus in a patient coinfected with HIV and HBV.
London, UK
2 hours ago
1 Received
- * Transcatheter arterial chemoembolization (TACE) is the primary treatment for intermediate-stage HCC, and recent studies suggest that combining it with targeted drugs and immune checkpoint inhibitors boosts treatment effectiveness.
- * A case involving a 57-year-old woman with HIV and HCC showed that a combination of TACE, donafenib, and tislelizumab resulted in a complete clinical response, highlighting a potential new approach for similar patients.
$100 - $150
Hourly Rate
Pituitary-adrenal axis dysfunction induced by tislelizumab immunotherapy for non-small cell lung cancer: a case series and literature review.
London, UK
2 hours ago
1 Received
- Some patients treated with tislelizumab, an immunotherapy for lung cancer, developed a rare condition called secondary adrenal insufficiency.
- The study looked at three patients, all middle-aged and smokers, who showed signs of this condition after several treatment cycles.
- They all had to stop their treatment and take glucocorticoid medicine to manage their symptoms, as their hormone levels didn’t return to normal.
$100 - $150
Hourly Rate
Tislelizumab synergizes with surgery to augment the survival benefit in stage II-III non-small cell lung cancer.
London, UK
2 hours ago
1 Received
- - This study analyzed the effects of tislelizumab (T) combined with surgery compared to just chemotherapy (C) on patients with stage II-III non-small cell lung cancer (NSCLC), focusing on progression-free survival (PFS) and overall survival (OS).
- - Results showed that patients receiving T had significantly higher response rates and surgery further enhanced survival outcomes, indicating that combining T with surgery is more beneficial than either treatment alone.
- - The findings conclude that using tislelizumab followed by surgery significantly improves survival for NSCLC patients, highlighting the importance of this treatment combination.
$100 - $150
Hourly Rate
[Expression and Clinical Significance of Cytokines and Lymphocyte Subsets in Patients with Diffuse Large B-Cell Lymphoma].
London, UK
2 hours ago
1 Received
- The study aims to investigate the role of cytokines and lymphocyte subsets in diagnosing and evaluating treatment effectiveness in patients with Diffuse Large B-Cell Lymphoma (DLBCL) and how Tislelizumab affects their immune function.
- A total of 23 DLBCL patients and 34 control patients with megaloblastic anemia were analyzed for various cytokines and lymphocyte levels using ELISA and flow cytometry.
- Results show significantly elevated levels of cytokines IL-2, IL-6, and IL-10 in DLBCL patients compared to the control group, and Tislelizumab treatment led to increased IL-2 levels and changes in T cell populations, indicating
$100 - $150
Hourly Rate
Systemic Therapy for Hepatocellular Carcinoma: Latest Advances.
London, UK
2 hours ago
1 Received
- * While no new drugs were successful from 2007 to 2016, the years 2017-2018 saw the launch of four effective drugs (regorafenib, lenvatinib, cabozantinib, and ramucirumab) following promising clinical trials.
- * Recent advancements include the application of immune checkpoint inhibitors, with ongoing trials for their use alone or in combination with other therapies, suggesting better outcomes with these combinations compared to using PD-1/PD-L1 inhibitors
$100 - $150
Hourly Rate
Nivolumab for the treatment of hepatocellular carcinoma.
London, UK
2 hours ago
1 Received
- T-cell checkpoint inhibition has emerged as a groundbreaking cancer treatment since the introduction of ipilimumab in 2011, with significant advances in research and drug development.
- Nivolumab, a PD-1 targeting monoclonal antibody, is approved for various advanced cancers and was specifically sanctioned for liver cancer in 2017 as a second-line treatment.
- Current trials are exploring the efficacy and safety of nivolumab and other immunotherapies for hepatocellular carcinoma, indicating a promising new treatment avenue for advanced cancer patients.
$100 - $150
Hourly Rate
RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma.
London, UK
2 hours ago
1 Received
- * Monoclonal antibodies targeting PD-1 have shown promise in treating solid tumors, including HCC, with Tislelizumab being a notable investigational drug that binds specifically to PD-1.
- * The text discusses a Phase III study that compares the effectiveness, safety, and tolerability of Tislelizumab versus Sorafenib as first-line treatments for patients with unresectable HCC.
$100 - $150
Hourly Rate
Antibodies to watch in 2019.
London, UK
2 hours ago
1 Received
- The 'Antibodies to watch' articles have tracked significant developments in antibody therapeutics over the past decade, focusing on approvals and regulatory reviews from the previous year.
- In 2018, the report highlighted a record number of 12 antibody therapies that received approval, reflecting a strong clinical development pipeline with over 570 candidates in various stages of development.
- Success rates for antibodies moving from Phase 1 trials to approval are favorable, varying between 17-25%, with distinct differences in rates for cancer-related versus non-cancer treatments.
$100 - $150
Hourly Rate
Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies.
London, UK
2 hours ago
1 Received
- Although classical Hodgkin lymphoma (cHL) is generally treatable, 20-30% of patients still face treatment failure, leading to further relapse or progression, especially after therapies like salvage chemotherapy and autologous stem cell transplantation (autoSCT).
- Recent immunotherapy advancements, including drugs like Brentuximab vedotin (BV) and immune checkpoint inhibitors (CPIs) such as nivolumab and pembrolizumab, have shown promising results for patients with relapsed/refractory cHL, providing prolonged remissions or disease stabilization even after multiple previous treatments.
- These newer therapies are being explored for use earlier in treatment protocols, with BV now approved for initial treatment of advanced stages of cHL and ongoing trials
$100 - $150
Hourly Rate
A Human Peripheral Blood Mononuclear Cell (PBMC) Engrafted Humanized Xenograft Model for Translational Immuno-oncology (I-O) Research.
London, UK
2 hours ago
1 Received
- The advancement of immuno-oncology (I-O) therapies marks significant progress in cancer treatment, but challenges remain in this field.
- The article introduces a humanized xenograft model using human peripheral blood mononuclear cells (PBMC) to help research immune checkpoint therapies like BGB-A317 (Tislelizumab) for their effectiveness against human tumors.
- This model is noted for being time and cost-efficient while providing reliable results, and the authors propose their protocol as a useful guide for creating similar models in I-O research.
$100 - $150
Hourly Rate
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
London, UK
2 hours ago
1 Received
- This study examines the combination of pamiparib (a PARP inhibitor) and tislelizumab (an anti-PD-1 antibody) to treat advanced solid tumors, focusing on safety and effectiveness.
- Conducted across five sites in Australia, the research involved adults over 18 years with prior treatments, using a dose-escalation method to identify the safest and most effective doses.
- The main goals were to assess safety, tolerability, maximum tolerated dose, and recommended doses for future larger trials, emphasizing thorough analysis of patient responses to the treatments.
$100 - $150
Hourly Rate
Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study.
London, UK
2 hours ago
1 Received
- - The study focused on the effectiveness and safety of tislelizumab, an anti-PD-1 monoclonal antibody, for Chinese patients with relapsed/refractory classical Hodgkin lymphoma (cHL) who can't undergo autologous stem cell transplant.
- - Out of 70 patients treated, 87.1% showed some level of positive response, with 62.9% achieving a complete response and a 9-month progression-free survival rate of 74.5%.
- - The treatment was generally well tolerated, though some patients experienced significant side effects, including infections and immune-related adverse events; importantly, no deaths were reported due to these side effects.
$100 - $150
Hourly Rate
Successful treatment of metastatic colorectal cancer with synchronous mutation and dMMR with BGB-A317.
London, UK
2 hours ago
1 Received
- Metastatic colorectal cancer with mutations is aggressive, has a poor outlook, and limited treatment options.
- The case involved a patient with a specific mutation and DNA mismatch-repair deficiency who faced postoperative recurrence and metastasis.
- Treatment with a new anti-PD-1 antibody called BGB-A317 led to continuous improvement in the patient's condition.
$100 - $150
Hourly Rate
Tislelizumab: First Approval.
London, UK
2 hours ago
1 Received
- Tislelizumab is a monoclonal antibody targeting the PD-1 receptor, developed by BeiGene as a treatment for certain cancers.
- It was approved in China in December 2019 for patients with relapsed or refractory classical Hodgkin's lymphoma after at least two prior chemotherapy treatments.
- The article highlights key developments in its approval process and discusses potential future indications for this drug.
$100 - $150
Hourly Rate
Lichen planus pemphigoides during therapy with tislelizumab and sitravatinib in a patient with metastatic lung cancer.
London, UK
2 hours ago
1 Received
$100 - $150
Hourly Rate
Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy.
London, UK
2 hours ago
1 Received
- Blocking the PD-1/PD-L1 interaction with monoclonal antibodies, like tislelizumab, has significantly improved cancer treatment outcomes.
- The crystal structure of PD-1 bound to tislelizumab shows that CDR3 from the heavy chain is crucial for this interaction, while the light chain contributes differently.
- Analyzing various therapeutic antibodies against PD-1 helps enhance our understanding of how to effectively inhibit this pathway in cancer immunotherapy.
$100 - $150
Hourly Rate
Association of Hypoactive and Hyperactive Delirium With Cognitive Function After Critical Illness.
London, UK
2 hours ago
1 Received
- Delirium is a complex condition linked to worse long-term cognitive outcomes in patients who have experienced critical illness, prompting researchers to explore how different types of delirium affect cognition over time.
- A study analyzed data from 582 patients in various hospitals, focusing on two subtypes of delirium: hypoactive (low activity) and hyperactive (high activity), measuring their impact on cognitive function at 3 and 12 months post-hospitalization.
- Results indicated that longer durations of hypoactive delirium were significantly associated with poorer global cognition and executive functioning after 3 months and continued to affect executive function at 12 months, while the presence of hyperactive delirium did not significantly alter these outcomes.
$100 - $150
Hourly Rate
Opportunistic bowel infection after corticosteroid dosage tapering in a stage IV lung cancer patient with tislelizumab-related colitis.
London, UK
2 hours ago
1 Received
- Immune checkpoint inhibitors are now a key cancer treatment, showing long-lasting effects in various tumors, but they can cause immune-related side effects like diarrhea, seen in about 10-13% of patients.
- Diarrhea should be accurately diagnosed as immune-related or infection-related, as mismanagement can complicate treatment.
- A case study of an advanced lung cancer patient highlights the need for careful monitoring and diagnostic testing, as the patient experienced recurring diarrhea after initial steroid treatment, eventually improving with antiviral and antibiotic therapies.
$100 - $150
Hourly Rate
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.
London, UK
2 hours ago
1 Received
- The PD-1/PD-L1 pathway is crucial for regulating immune responses against tumors, and the investigational antibody tislelizumab aims to enhance antitumor immunity while reducing potential resistance by limiting macrophage interaction.
- In a phase IA/IB study involving 451 patients with advanced solid tumors, various doses and schedules of tislelizumab were tested for safety and effectiveness, monitoring adverse events and antitumor responses.
- Common side effects included fatigue and nausea, with a low rate of serious adverse events; overall, 18% of patients in phase IA and 12% in phase IB showed confirmed positive responses, indicating potential efficacy of the treatment.
$100 - $150
Hourly Rate
Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study.
London, UK
2 hours ago
1 Received
- - Tislelizumab is a new monoclonal antibody designed to inhibit PD-1, aimed at enhancing anti-tumor activity by reducing T-cell clearance that can lead to resistance against similar treatments.
- - A phase 1/2 study assessed its safety and effectiveness in treating advanced solid tumors in adult Chinese patients, confirming a recommended dosing of 200 mg every three weeks and monitoring for adverse effects.
- - Out of 300 treated patients, 18% demonstrated a confirmed clinical response, with mild side effects predominantly reported, such as anemia and increased liver enzymes.
$100 - $150
Hourly Rate